Biogen Inc. (BIIB) Earnings Call Transcript & Summary

February 3, 2021

NASDAQ US Health Care Biotechnology earnings 67 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Thanks, Jake. Hello everyone, and welcome to the Biogen earnings call for the fourth quarter of 2020. Before we get started, please visit the Investors section on biogen.com, where you'll find the earnings release along with the related financial tables — this includes our GAAP financial measures and a reconciliation between GAAP and the non-GAAP financial measures we'll be talking about today. Tables 1 and 2 contain our GAAP financials, and Table 4 provides a reconciliation of our GAAP results to our non-GAAP financial results. In our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage it internally. We've also put slides up on our website that go along with the discussions for this call. Before we go further, I want to note that some of what we say today will look ahead, reflecting what we currently expect and believe. A number of risks and uncertainties could affect those statements, so what actually happens might be quite different. For a fuller picture, please review the risk factors laid out in the documents we file with the SEC. Joining me on this call are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, our EVP, Research and Development; and Mike McDonnell, our CFO. Michel, over to you.

Michel Vounatsos

executive
#2

Hello, everyone, and thanks for being with us today. To begin, I want to express gratitude to Joe Mara for everything he has contributed to Biogen over these past 14 years, and to congratulate him on a promotion he truly deserves. I'm also very happy to welcome Mike Hencke, who is taking on that role. As was announced last week, the FDA has pushed back the review period for aducanumab in the U.S. to June 7; we will work closely with the FDA while it finishes reviewing the aducanumab application, and our clinical data continues to have our full confidence; in our view, the results we have support approval. Now let me walk through the year. For society broadly and for our industry as well, 2020 brought a great deal of uncertainty because of COVID-19. And what the Biogen team accomplished makes me proud. Across the full year 2020, Biogen brought in $13.4 billion in revenue, which is a 6% decline compared with the prior year, reflecting the erosion of TECFIDERA revenue in the U.S. from the impact of generic entry. Non-GAAP earnings for full year 2020 came to $33.70 per share, a modest rise over full year 2019. Let me now go through how we have progressed on our strategic priorities. First, MS revenues for the full year, which include OCREVUS royalties, totaled $8.7 billion, down 6% from the prior year. If you set aside TECFIDERA in the U.S., our global MS revenue was fairly flat for both Q4 and the full year compared with 2019. Launching a new product during COVID-19 comes with difficulties, yet we were glad to see trends improving strongly for VUMERITY, which in the U.S. has become the number two MS product and the number one overall when it comes to new prescriptions. These results, in our view, show that we can sustain leadership and execute effectively, even with greater competition, the erosion of TECFIDERA revenue in the U.S. and COVID-19. Second, SPINRAZA brought in full year global revenues of $2.1 billion, which is a 2% decline from the prior year. Q4 global revenues held steady compared with Q3. Although SPINRAZA faces greater competition in the U.S., made worse by the effects of COVID-19, growth outside the U.S. continued and offset that. We stay dedicated to exploring further how outcomes for patients on SPINRAZA might be enhanced. That includes the DEVOTE study, which tests a higher dose, along with the recently started RESPOND study, which evaluates SPINRAZA in patients whose clinical response to gene therapy has been sub-optimal. Significant questions about the other approved treatment options still lack answers. And we are dedicated to producing relevant data so that treatment choices can be better informed. In the treatment of SMA, our view is that SPINRAZA will keep serving as a foundation of care. Third, biosimilars turned in solid performance even as COVID-19 continued to have an impact, posting revenues of $796 million for 2020, which amounts to 8% growth year-over-year. We estimate that biosimilar use produced roughly €2.4 billion in savings for the European Health Care Systems in 2020, which ought to help broaden access and open up headroom for new innovation. Additionally, we achieved significant strides regarding possible geographical growth and upcoming expansion for the biosimilars division by submitting SB11, which references LUCENTIS within the United States, a market where biosimilars should produce upwards of $100 billion in savings across the coming 5 years. Number four, 2020 proved to be an extremely favorable period for our R&D group. During the prior year, we filed for regulatory approval of aducanumab across the U.S., EU and Japan; we continue to be prepared to introduce aducanumab within the U.S. should it secure approval, whenever that may be. Our teams examined specialist availability, infusion capacity, the capability to verify amyloid beta pathology, MRI capacity along with formulary approval processes. We think there exist several 100 sites throughout the U.S. that stand ready to begin treating patients if aducanumab gains approval. Past aducanumab, we progressed or moved forward 12 fresh clinical programs during the last year spanning MS, ALS, Parkinson's disease, depression, and biosimilars, among them for in Phase 3. Crucially, we established new strategic collaboration with Sage and Denali, granting access to potential first-in-class treatments for serious neurological disorders, for instance depression and Parkinson's disease. Our partnership with Sage brings important late stage diversification via Phase 3 programs covering both major depressive disorders and postpartum depression, with critical readouts anticipated during this year, and an asset in depression would deliver multiple synergies throughout Biogen's current portfolio. Broadly in 2021, we anticipate eight mid to late stage data readouts, among them four programs in Phase 3. Number five, our cash flow generation keeps giving us considerable flexibility to allocate capital. Throughout 2020, we gave back roughly $6.7 billion of capital to shareholders and directed approximately $3 billion toward business development to strengthen our pipeline. To sum up, 2020 was an extremely productive year for the company as we have carried out our strategy. In spite of the difficulties from COVID-19 and TECFIDERA generics, we have sustained global leadership throughout our core businesses in MS, SMA and biosimilars, and we have achieved significant progress toward constructing a multi franchise portfolio. As Mike will detail alongside our guidance, we believe 2021 will represent a reset year for the company financially on both the top and bottom lines, yet we believe we can expand the company over the long-term. As we have shown previously, we are dedicated to maximizing returns for our shareholders, as we strive to bring innovative therapies to patients. I will now hand the call over to Al for a more detailed update on our recent progress in R&D.

Alfred Sandrock

executive
#3

Thank you, Michel, and good morning to all of you. First, I want to express my gratitude to my R&D teammates for their commitment to finding and creating new, potentially transformative treatments for patients who need them. Thanks to their efforts, Biogen experienced a year full of landmark achievements in 2020. Our work toward establishing a portfolio spanning multiple franchises has advanced considerably, with 10 programs now either in Phase 3 or already submitted across several important therapeutic areas. After over a decade of effort focused on bringing forward the first therapies addressing the underlying pathophysiology of Alzheimer's disease, we take pride in having finished regulatory submissions for aducanumab across multiple regions. Our hope is that these submissions open the door to the first treatments capable of slowing the relentless clinical deterioration experienced by Alzheimer's patients worldwide. In addition, our partners at Eisai launched the AHEAD 3 to 45 trial, which was designed to assess whether BAN2401 could offer benefit to individuals with early Alzheimer's pathology even before cognitive impairments become apparent to them. Last, we strengthened both our early and late stage pipeline through internal work as well as partnerships with prominent neuroscience firms, among them Denali, Sage and Sangamo. Now let me shift to what we achieved during the fourth quarter, beginning with Alzheimer's disease and dementia. The aducanumab clinical trials were the first to demonstrate, in randomized double-blind placebo controlled studies, that an antibody targeting aggregated forms of amyloid leads to robust clearance of amyloid plaque and lessens clinical decline in Alzheimer's disease. Eli Lilly recently disclosed findings from the Phase 2 trial of donanemab, a different anti-amyloid antibody for Alzheimer's disease; those top line results show that donanemab has become the third molecule, following aducanumab and BAN2401, to demonstrate that antibodies aimed at amyloid plaque, producing a strong impact on plaque reduction, also yield clinical benefit. The Phase 2 results observed with donanemab matched what aducanumab showed in its Phase 3 trials regarding amyloid plaque reduction as measured in centiloid, and also regarding clinical effect as measured on a composite scale of ADAS-Cog activities of daily living; we intend to share more specifics on this data at the AD/PD meeting coming up in March; this data keeps reinforcing our conviction that antibodies directed at the forms of a-beta concentrated in amyloid plaque could deliver therapeutic advantages, setting these molecules apart from earlier anti-amyloid antibodies. Consequently, we feel optimistic about BAN2401's prospects as it is being assessed right now in the Clarity Phase 3 trial. Target enrollment for Clarity was recently raised by roughly 200 patients to address COVID-19 related dosing difficulties, in discussion with the FDA. Even so, the expected readout timing of Q3 2022 stays the same. Beyond anti-amyloid treatments, we keep pursuing several strategies that target tau. When tau becomes misfolded, it turns into the main building block of neurofibrillary tangles, which represent yet another characteristic feature of Alzheimer's disease pathology. From the Phase 2 trial of gosuranemab — our anti-tau antibody designed to stop tau from spreading throughout the brain — we anticipate data during the first half of this year. We also have BIIB080, an antisense oligonucleotide aimed at tau that is intended to lower production of every form of tau. Working alongside Ionis, we learned not long ago that in the Phase 1b multiple ascending dose study involving patients with mild Alzheimer's disease, treatment with BIIB080 was generally well-tolerated and produced a reduction from baseline in CSF total tau and phospho-tau that was dependent on dose and time, with the effect proving durable. Additional details are slated for presentation at a scientific meeting coming up. Right now we are completing our plans to move BIIB080 forward into a Phase 2 study in Alzheimer's disease. To sum up, across amyloid and tau, plus other targets still in the preclinical stage, we are pushing ahead an industry-leading pipeline that aims to change how Alzheimer's disease progresses. Shifting to MS, we've achieved substantial progress in strengthening the MS franchise we already have. This covers the approval of intramuscular PLEGRIDY in the United States and in the European Union, a positive CHMP opinion for subcutaneous TYSABRI, and the filing of a marketing authorization application for VUMERITY in the EU. In addition, we anticipate a readout for the NOVA study — which assesses how efficacious extended interval dosing of TYSABRI is — by midyear. We lately brought BIIB107, an antibody directed at alpha4 integrins, into our MS pipeline. TYSABRI, a highly efficacious therapy for relapsing MS, has proven the clinical value of hitting alpha4 integrins. BIIB107 is a new molecular entity showing higher binding affinity, decreased Fc effector function, and a predictable pharmacological effect in preclinical research. Our goal is to fold in everything we've learned from TYSABRI, extended interval dosing included, so that we can optimize safety, the dosing regimen, and patient convenience while preserving TYSABRI's high efficacy. When it comes to neuromuscular disorders, we intend to keep improving the therapeutic benefit of SPINRAZA, and we announced recently that the first patient has been dosed in the RESPOND study, which will assess the effect of SPINRAZA among patients whose clinical response to gene therapy has been suboptimal. We are also still enrolling patients in the DEVOTE study, which is evaluating whether higher doses of SPINRAZA can deliver greater efficacy than the dose approved at present. In ALS, we recently enrolled the final patient in the Phase 3 trial evaluating tofersen in SOD1 ALS, and we look forward to the readout in the second half of this year. In movement disorders, we were disappointed to learn that the Phase 2 study of BIIB054 in Parkinson's disease did not meet the primary or secondary endpoints. Drawing on our Phase 1 results from CSF samples involving BIIB054, we think the doses we tested in the Phase 2 trial were adequate to engage extracellular alpha-synuclein within the central nervous system. Consequently, we've made the decision to halt further development of BIIB054, and we intend to present detailed studies at a future scientific — study results at a future scientific meeting. Even so, we feel the study delivers a high-quality clinical data set that can guide our future reference in Parkinson's disease. Denali recently announced completion of the Phase 1b study for BIIB122, also known as DNL151, a small molecule inhibitor of LRRK2 that achieved its target and pathway engagement goals. We anticipate launching late stage clinical development in Parkinson's disease patients by the end of this year. In stroke, TMS finished enrollment for the Phase 2 trial of TMS-007 in acute ischemic stroke in Q4 of 2020, and we're excited about the upcoming readout anticipated in the first half of this year. TMS-007 is a small molecule modulator of plasminogen, and the hypothesis is that it facilitates thrombolysis selectively at the site of the clot while at the same time exerting an anti-inflammatory effect that helps reduce the risk of additional tissue damage. We believe the targeted mechanism of action of TMS-007 could yield significant advantages over recombinant tissue plasminogen activator, or TPA, which currently remains the standard of care for ischemic stroke.

Alfred Sandrock

executive
#4

That covers the possibility of stretching the therapeutic window out to 12 hours or more, versus the 3 or 4.5 hour window that TPA offers, while lowering the chance of problematic bleeding episodes. Given all that, our view is that TMS-007 could be a best-in-class thrombolytic agent; enrollment is ongoing in the Phase 3 study of BIIB093, which targets cerebral edema stemming from large hemispheric infarction, even with the difficulties created by the COVID-19 pandemic. Last, business development had a highly productive quarter, as we completed several collaborations giving us access to innovative therapies with potential to be first-in-class. Markedly speeding up our move into neuropsychiatry, we signed a collaboration with Sage, which leads the psychiatry field. Major depressive disorder, or MDD, along with postpartum depression, or PPD, are extremely common conditions, and our belief is that zuranolone, Sage's lead asset, could become a first-in-class oral treatment for each. We anticipate several upcoming Phase 3 readouts for zuranolone during this year, among them WATERFALL, covering episodic treatment of MDD; CORAL, covering rapid response therapy when started alongside standard anti-depressive therapy and MDD; and SKYLARK in PPD. In addition to zuranolone, we will work together on SAGE-324, which is presently being developed for essential tremor, with data from the Phase 2 study expected in early 2021. Deepening our dedication to ophthalmology, we signed a collaboration with ViGeneron aimed at creating gene therapies for inherited retinal diseases; through this partnership, our goal is to deploy ViGeneron's proprietary AAV capsids to efficiently transduce retinal cells through intravitreal injections, which might be deliverable in the clinic and could provide efficacy through substantially greater retinal area coverage relative to sub-retinal injection performed surgically. More recently, we signed a collaboration with Atalanta Therapeutics built on technology originating from the RNA therapeutics Institute at the University of Massachusetts, founded by Nobel laureate Dr. Craig Mello. Under this partnership, Atalanta will apply its proprietary branched siRNA platform toward developing possible treatments for multiple CNS targets, among them HTT for treating Huntington's disease; this Atalanta collaboration, together with our recent ones involving Sangamo, Scribe, ViGeneron and the Massachusetts Eye and Ear Infirmary, plus our long-standing collaboration with Ionis, broaden our ASO and RNAi capabilities and support our continuing gene therapy work, such as developing our gene therapy assets for inherited retinal disorders. In addition, we established a gene therapy accelerator unit dedicated to addressing the field's key technological challenges, with the aim of bringing more gene therapies to market that could change patients' lives. During 2020, Biogen R&D built and advanced a cutting edge neuroscience pipeline, applying state-of-the-art therapeutic modalities against drug targets with strong genetic validation. Consequently, we feel we are well-positioned for growth in a transformative year, with eight clinical trial readouts anticipated, four of them pivotal programs. We stay optimistic about the opportunities in front of us. We think a promising era is arriving for neurotherapeutics and what they can do to meaningfully affect patients' lives, which could include potentially delivering the first therapy that changes the course of Alzheimer's disease. Now I'll hand the call to Mike.

Michael McDonnell

executive
#5

Thanks, Al, and good morning to all of you. Despite headwinds from COVID-19 and U.S. generics of TECFIDERA, Biogen delivered another solid quarter, as we keep executing well and holding global leadership positions across our core businesses; our financial position remains very strong, with substantial cash and financial capacity to keep growing the business over the long term. I'll now walk through our financial performance for the quarter and also share our guidance for 2021. Fourth quarter total revenue came in at $2.9 billion, down 22% from the prior year on both an actual and constant currency basis. Full year total revenue was $13.4 billion, a 6% decline versus the prior year at both actual and constant currency. That decrease was largely the result of generic entry for TECFIDERA in the U.S. Fourth quarter total MS revenue, which includes OCREVUS royalties of $1.8 billion, fell 24% versus the prior year on both an actual and constant currency basis. Full year total MS revenue, including OCREVUS royalties of $8.7 billion, was down 6% versus the prior year at actual currency and down 5% at constant currency. This decline was likewise driven by the arrival of multiple TECFIDERA generics in the U.S. If you exclude U.S. TECFIDERA, total MS revenue including OCREVUS royalties was roughly flat for both the fourth quarter and the full year versus the prior year, which shows how resilient our MS business is in a competitive market. Global TECFIDERA revenue in the fourth quarter was $608 million, a 48% decline versus the prior year, while full year revenue of $3.8 billion fell 13%. Outside the U.S., fourth quarter TECFIDERA revenue reached $288 million, up 1% versus the prior year, and full year revenue of $1.2 billion rose 3%, with patients continuing to grow. During the quarter, VUMERITY trends kept improving. VUMERITY revenue totaled $39 million in the fourth quarter. TYSABRI fourth quarter global revenue was $475 million, roughly flat versus the prior year, and full year revenue of $1.9 billion grew 3% for the full year. We were pleased to see patients grow globally throughout the year and believe TYSABRI is well-positioned to play an increasingly important role in treating MS as we advanced several important initiatives, including subcutaneous administration and extended interval dosing. Turning now to SMA. Global fourth quarter SPINRAZA revenue was $498 million, down 8% versus the prior year at actual currency and down 10% at constant currency; in the U.S., SPINRAZA revenue declined by 34% versus the prior year as we see competition having an impact, which COVID-19 has made worse. Outside the U.S., SPINRAZA revenue rose 13% versus the prior year, with strong growth in emerging markets, partly offset by maturation of larger European markets. For the full year, global SPINRAZA revenue of $2.1 billion was down 2% versus the prior year at actual currency and down 1% at constant currency. Full year U.S. SPINRAZA revenue fell 16%, and full year revenue outside the U.S. grew 9%. Even though fresh rivals and COVID-19 have left their mark on SPINRAZA, as Michel and Al explained, our view is that this drug possesses an exceptionally robust efficacy and safety profile and will remain a cornerstone of treatment. Now on to biosimilars. Revenue for the fourth quarter came in at $197 million, which was unchanged from the same period a year earlier in actual currency terms, while dropping 4% on a constant currency basis. For the entire year, revenue reached $796 million, an 8% gain over the previous year in actual currency and a 6% gain in constant currency. Pricing pressure keeps weighing on our biosimilars segment, compounded by fewer new treatments starting and diminished clinic capacity stemming from COVID-19. Even with COVID-19's ongoing effects, we remain the top anti-TNF biosimilar supplier in Europe, and BENEPALI is still the most prescribed etanercept product throughout Europe; we see room to keep expanding in Europe, and also in the U.S. and other regions, by bringing to market new products from our Samsung Bioepis JV along with other biosimilar offerings. Anti-CD20 revenue overall for the fourth quarter totaled $419 million, a 30% drop from the prior year, reflecting roughly level OCREVUS royalties alongside a 45% decline in RITUXAN revenue. For the whole year, total anti-CD20 revenue was $2 billion, down 14% from the previous year, with OCREVUS royalties rising 23% and RITUXAN revenue falling 29%. The RITUXAN decline stems from COVID-19's effects and faster erosion caused by biosimilars. Now shifting to gross margin. Gross margin in the fourth quarter represented 83% of revenue, compared with 88% during the same quarter of 2019. This drop resulted from lower TECFIDERA and RITUXAN sales—both high-margin items—plus elevated costs tied to our corporate partner revenue because of product mix. For all of 2020, gross margin stood at 87%, up against 86% in 2019. Turning to expenses now. Non-GAAP R&D expense for Q4 was $642 million, which includes $68 million connected to external collaboration agreements with Scribe, Atalanta and ViGeneron. Non-GAAP R&D expense across the full year came to $2.1 billion. Non-GAAP SG&A for Q4 was $793 million, encompassing roughly $100 million tied to launch preparations for aducanumab. Full year non-GAAP SG&A reached $2.5 billion, with approximately $250 million of that related to aducanumab; during Q4 of this year, our effective non-GAAP tax rate was about 16%, matching the fourth quarter of 2019. For the full year, our effective non-GAAP tax rate was roughly 18%, compared with approximately 16% in 2019. In the fourth quarter, we bought back 1.6 million shares of the company's common stock, spending $400 million in total. Across 2020, we bought back 22.4 million shares for a total of $6.7 billion. As of December 31 2020, $4.6 billion was left available under the share repurchase program authorized in October of 2020. Our weighted average diluted share count came to approximately 154 million shares for the fourth quarter and 161 million shares for the full year. For Q4, non-GAAP diluted EPS came in at $4.58. Looking at the whole year, non-GAAP diluted earnings per share reached $33.70 — that's up $0.13 from the previous year and ahead of the range we most recently guided to. During 2020, net cash flow from operations came to roughly $4.2 billion. Full-year capital expenditures totaled $425 million, while free cash flow amounted to about $3.8 billion. At year-end, we held $3.4 billion in cash along with marketable securities, plus $7.4 billion of debt, which nets out to $4 billion in net debt. On top of that, our $1 billion revolving credit facility had no balance drawn when the year closed. Now I'd like to discuss our guidance for the full year 2021. For the full year 2021, we anticipate revenue ranging from $10.45 billion to $10.75 billion; non-GAAP diluted EPS somewhere between $17 and $18.50 per share; and capital expenditures in the range of $375 million to $425 million; I want to emphasize that this guidance rests on several critical assumptions that are presently uncertain. Should those assumptions shift, our results could be materially affected. Our guidance presumes aducanumab will secure U.S. approval by June 7, though the FDA's decision still carries uncertainty.

Michael McDonnell

executive
#6

Assuming aducanumab gets the green light in the U.S., our expectation would be to launch right away. That said, the titration process means we'd see reduced revenue per patient during the first few months of treatment. Consequently, for aducanumab in 2021 we'd anticipate just modest revenue, with growth building after that. Once commercialization happens, we would record 100% of net revenue in the U.S., and a 45% profit share for A would go into a separate line item, not counted within R&D or SG&A. Beyond that, although erosion of our U.S. TECFIDERA business has so far been slower than we anticipated, should our legal appeals fail, we foresee a sharp decline across the first half of 2021, and that assumption is baked into our guidance. We likewise anticipate substantial erosion of RITUXAN in the U.S. Together with TECFIDERA, the revenue reduction from these high margin products is expected to weigh on our gross margin percentage. As a further reminder, during Q2 of 2020, we booked $330 million in revenues tied to the one-time license of certain manufacturing related intellectual property, which carried 100% gross margin; we anticipate non-GAAP R&D expenses falling between $2.35 billion and $2.45 billion. Through ongoing investment in our pipeline, we stay dedicated to long-term growth, and that pipeline has now expanded to 33 programs in total spanning 10 therapeutic areas, among them 10 programs sitting in Phase 3 or filed. Crucially, we anticipate eight important mid to late stage readouts from our pipeline during this year, four of which are in Phase 3. Our expectation for non-GAAP SG&A expenses is a range of $2.6 billion to $2.7 billion. Within that estimate sits an investment of roughly $600 million to support the potential aducanumab launch. Around $200 million of that figure would be reimbursable by Eisai, reflected as collaboration profit sharing once commercialization occurs rather than as part of SG&A; furthermore, note that we've devoted a significant share of our manufacturing capacity to aducanumab, which might affect 2021 results should aducanumab fail to win approval. For 2021, we expect our non-GAAP tax rate to land between 16% and 17%, and we assume we'll draw on a portion of the $4.6 billion remaining share repurchase authorization over the course of the year, though that hinges on various factors, among them our business development activity. We've assumed foreign exchange rates as of December 31, 2020 will hold for the year, net of hedging activities. And we've factored in no impact from potential tax or health care reform, nor from any potential acquisitions or large business development transactions. Looking ahead, our plan is to refresh full year financial guidance on a quarterly basis. At this point I'll hand the call back to Michel for his closing comments.

Michel Vounatsos

executive
#7

Thanks, Mike. In 2020, Biogen showed it could weather challenges and execute effectively, putting us in a good position to handle the effects of TECFIDERA generics and to make 2021 a year of transformation for the company as we keep carrying out our strategy of building a portfolio with multiple franchises. We're moving forward an industry-leading pipeline for Alzheimer's disease, and we're awaiting a key U.S. decision on aducanumab, now anticipated by early June. As AI described, our confidence in the therapeutic approach of targeting amyloid plaques has never been greater. We believe our data backs approval of aducanumab, and we're optimistic about BAN2401 one in Phase 3. We're also pursuing complementary approaches that target tau pathology, with three clinical assets aimed at extracellular tau via an antibody or intracellular tau via an ASO. We start 2021 with a broader, more diversified pipeline, and we expect eight mid- to late-stage readouts before this year ends. Those consist of four pivotal and four Phase 2 readouts spanning multiple therapeutic areas marked by substantial unmet medical needs, including ALS, stroke, and the new Phase 3 programs in MDD and PPD with Sage. We also anticipate meaningful milestones across our core business this year. In MS, we're launching intramuscular PLEGRIDY, and we're preparing for a possible launch of subcutaneous TYSABRI, plus important data on extended interval dosing around the middle of the year. As we build for the medium to long term, our goal is to scale our digital capabilities to better address patients' needs. As part of our vision to lead in Alzheimer's disease, we're excited to work with Apple on developing potential digital biomarkers that could help diagnose and monitor disease progression at an earlier stage of cognitive decline. I want to restate our commitment to maximizing shareholder returns and delivering innovative therapies to patients over the long term. That requires us to keep allocating capital efficiently, effectively, and appropriately. As we've shown before, we'll always seek an optimal capital structure while aiming for superior returns on the investments we make. Finally, I'd like to reflect on Biogen's long-standing commitment to corporate responsibility. Our dedication to patients and to broader society isn't only about developing novel therapeutics for people suffering from serious diseases — it goes much further. At Biogen, we take a holistic view of health and strive to improve the broader society we serve; now, more than ever, we keep investing in climate and health, access and equity, and diversity and inclusion. In closing, I want to thank our employees around the world, who've shown dedication to making a positive impact on patients' lives, and all the physicians, caregivers, and participants in our clinical development programs — our past and future achievements couldn't happen without passion and commitment. We'll now open the call for questions.

Michel Vounatsos

executive
#8

Max Skor here, calling in on behalf of Matthew Harrison — apologies for that. Could you walk us through how the RESPONSE study was designed? What counts as a suboptimal response to gene therapy, in your definition? And regarding enrollment, what timeline are you expecting for getting the study fully enrolled? Thanks. Thanks for asking. I'll take that one. Essentially, this shows how dedicated we are to giving clinical practice the best possible information, built on the new modalities we now have, for the good of and to the benefit of patients. That same approach reflects how we think about SPINRAZA serving as the foundation of care when treating SMA. Al?

Alfred Sandrock

executive
#9

Correct. Roughly 60 patients are going to be enrolled in the RESPONSE study, and enrollment hinges on a doctor's judgment that RESPONSE is not optimal — using CHOP INTEND scores as one example. Down the road, we might push for additional ways of measuring a suboptimal response as well. That said, the study will run for 2 years, and what we'll be evaluating is whether motor milestones measured on a scale — the Hammersmith score, for instance — get better when a SPINRAZA is added.

Terence Flynn

analyst
#10

Good morning, and thanks for taking my questions. Mine has two parts. First, Michel, I was hoping you could offer some insight into why the aducanumab approval got factored into your guidance. Second, whatever you're able to say right now about how you're approaching pricing in general — I realize you likely won't get into specifics, but could you speak at a high level? Do you view this as a specialty-priced drug rather than a primary care biologic, and have payers given any early signals? Thank you.

Michel Vounatsos

executive
#11

At its core, putting that guidance out there is the clearest reflection of the way we expect the business to move forward. Granted, these are suppositions we ourselves settle on, ones that might not match what actually unfolds ahead, which is essentially the industry we operate within. Still, this is the strongest conviction we hold as we speak right now. On the matter of price, we're approaching that point; we've held very extensive discussions with numerous stakeholders. Fundamentally, two principal aspects exist. The initial one concerns clinical meaningfulness, and possibly with regard to cognitive functions, yet also functional dimensions tied to activity of daily living. That's one side of the equation. The other side involves what Alzheimer's costs society, which currently exceeds $550 billion annually across the U.S. Then there's the expense of caring per patient, and unless I'm wrong, that's beyond $0.5 million. Once patients reach age 80, 75% of them reside in nursing home settings, and that runs over $100,000 each year; those are the key elements we weigh in our broad engagement on the significant subject of price we're approaching, as I mentioned, but it's too early to offer further specifics.

Marc Goodman

analyst
#12

Yes, good morning. Regarding adu, we're all just trying to get our heads around the fact that — considering how closely you've been collaborating with the FDA and for how long, plus the volume of data they've already received — it's difficult for us to see what more they might require, what gaps remain. So I was hoping you could shed some light on that. Did they request any specific data from the EMBARK study? Any additional clarity on where things stand would be useful. Then second, on SG&A, that $600 million you're committed to — could you explain how the spend will be gated? Is it tied to launch? In other words, does all of it land in the second half of the year? Or does half fall in the first half? I'm just trying to figure out, if adu isn't approved midway through the year, how much of that spending will actually happen? Thank you.

Michel Vounatsos

executive
#13

Thanks for the great question. I'll handle the first part — pardon me, the second part regarding SG&A, and Al will return to the data side, the important data side. So as for SG&A, essentially there's only a single chance for us to potentially launch such a significant product effectively; so we've aimed to execute a major launch for what may be the first product capable of bringing meaningful clinical and functional benefit to patients suffering from this disease, and that's potentially 10 million patients in the U.S. It represents a multibillion opportunity for the company. We're resourcing to win. Al?

Alfred Sandrock

executive
#14

Right, so we've consistently stated that a review is underway. Typically, while that review is happening, the FDA will ask for information; and not long ago, they made a request that called for us to hand over extra analyses along with clinical data; this resulted in a significant amendment, which in turn pushed back the PDUFA date. Other than that, I'd rather not go into greater depth regarding the particulars.

Michel Vounatsos

executive
#15

Regarding the sequence portion of your second question, Mike is going to add some further detail.

Michael McDonnell

executive
#16

Yes. Marc, good morning. There are a few things worth flagging. Clearly, if approval doesn't come through, we'll pace the spending as carefully as we can. You shouldn't assume we could offset all of those costs, though a significant chunk could be offset, and naturally we'd push to offset as much as possible. Another thing to keep in mind: within the U.S., nearly every cost tied to aducanumab falls under our Eisai arrangement, and in the U.S. that's reimbursable at 45%. So in the guidance we provided, that $600 million sitting in SG&A, roughly $200 million of it is reimbursable, and that portion would show up on a separate line of our P&L, on our collaboration sharing line. The explanation for why that ratio isn't quite what you'd anticipate is that the accounting gets complicated, and it shifts somewhat before versus after launch. A portion of the Eisai reimbursements is in fact netted within that $600 million, while the remainder flows through the collaboration line. Ultimately, though, from an economic standpoint, it's a 45% reimbursement schedule, and that's worth keeping in mind.

Umer Raffat

analyst
#17

Thank you very much for allowing me to ask. Al, I simply wanted to get a sense of your perspective on the new information coming out of the EMBARK redosing trial. And what I'm trying to figure out, I suppose, is this: if you take, say, those initial interim 24-week efficacy findings, do you place them alongside the final data point for each individual patient as they exit Phase 3? Or instead, are you putting the curve from those first 24 weeks up against the curve from the opening 24 weeks of the EMERGE and ENGAGE Phase 3 trials? What makes that tricky, I'd imagine, is that during the initial 24 weeks, those first two Phase 3 studies were titrating the dose. I'm just interested in how you approach that. Thanks.

Alfred Sandrock

executive
#18

Hello, Umer. Yes. Appreciate it. Yes, so enrollment for EMBARK is still ongoing. We've gotten partway through signing people up. It's true that the earliest look, which was shared at the meeting held recently, covers roughly a 6-month period. However, a number of the concerns you've raised are valid ones that the analytical plan will have to tackle; still, yes, patients continue to be enrolled; this is a significant trial, and ideally we'll wrap up enrollment before long, within the first half or thereabouts of this year.

Cory Kasimov

analyst
#19

Great, thank you, and thanks for taking my question. Good morning, everyone. So regarding AI, I just want to follow up on the EMBARK question. Is it the case that you're evaluating this in a way where, if the FDA needed information or requested it, you would be in a position to supply it? And then, could you also frame the upcoming Phase 2 readout for BIIB092, your anti-tau antibody, which is expected in the first half — sort of walk us through the trial design again and what you're hoping to demonstrate? Thank you.

Alfred Sandrock

executive
#20

Yes, thank you, Cory. Absolutely, we'll work to give the FDA everything they've requested through their information request. If that means examining studies that are still recruiting participants or are ongoing, then we'll do that. When it comes to BIIB092, the goal is to see whether it can affect how Alzheimer's progresses in these patients, who are mostly in the early stages. In Phase 1 trials, BIIB092 demonstrated a significant reduction in extracellular tau. The idea behind it is that we'll prevent tau from moving between cells. That's the hypothesis—that tau spreads in a prion-like manner in Alzheimer's disease. Over roughly a twelve-month period, we'll find out if our approach changes how Alzheimer's disease advances, as judged by the standard clinical assessments.

Evan Seigerman

analyst
#21

Hello, everyone. I really appreciate you taking my question. Al, I'm referring to something you said before, about 2021 being a year of reset. If we set aducanumab aside, though, how do revenue and earnings increase in 2022 and afterward? What I'm genuinely trying to figure out is whether your outlook and those remarks of yours rest mainly on aducanumab, or whether there are other meaningful drivers we ought to consider and mention. Thanks.

Michel Vounatsos

executive
#22

Mike?

Michael McDonnell

executive
#23

Absolutely, and I appreciate you asking that. We mentioned during our prepared comments that we're confident in our capacity to expand this business over a longer horizon. Clearly, aducanumab serves as the catalyst. That said, there are plenty of other highly promising opportunities on our side. Our portfolio includes 33 programs, with 10 of them sitting in Phase 3. As we've discussed before, 8 readouts are coming in 2021, and four of those are in Phase 3. I'd also direct your attention to our marketed products, which are gaining ground across numerous international markets. Regarding Biosimilars, I'd say much the same. Our pipeline is extremely robust. Sage, I believe, is an excellent addition, and there are more beyond that. So while aducanumab is clearly the catalyst, we're confident about our ability to grow this company over the longer term, grounded in what's in the pipeline along with the other elements I just referenced.

Michel Vounatsos

executive
#24

Thus, we anticipate numerous data readouts during this year. That is the reason I described the year as transformative. Even if a financial reset occurs, transformative regarding data readouts, which is in some way unprecedented for this company, with 4 Phase 3 trials and 4 Phase 2 trials. And regarding the greatest potential according to epidemiology, that is certainly MDD and PPD; so we — for which the late stage, they achieved positive readouts in randomized studies in PPD and MDD, and we remain hopeful. And past those, there is EYLEA <<inaudible>> and ALS in Phase 3. But past aducanumab, this pipeline is advancing quite well. And the core business is robust, it is resilient, and we depend on that. On the financial side, we hold cash and we can keep complementing this pipeline. So there are ample reasons for confidence.

Michael Yee

analyst
#25

Morning, and thanks for taking the question. Al, I'd like to follow up on what you said regarding Lily. Do you think that data is building more confidence among scientists and perhaps among regulators? Their design was quite interesting, though they relied on a different endpoint, and clearly that drew people toward placebo. So perhaps you could pick up where you left off, Al, with those remarks, and address how you view this in light of even the Alzheimer's community, where some very vocal voices are focused on a-beta.

Alfred Sandrock

executive
#26

Right, I'd say it lends support to the amyloid hypothesis and backs the idea of going after amyloid in Alzheimer's disease at early stages. Lily started work on this antibody and first put out publications on it back in 2012. What they discovered was that clearing plaque that was already there required pursuing — required employing an antibody capable of reaching the plaque, and in animals they demonstrated that the pyroglu-specific antibody accomplished that; now they've verified the same result occurs in people through amyloid PET imaging. It's wonderful to see they appear to demonstrate an impact on clinical decline as well. Their measure was a composite of ADAS-Cog and IADL, which in my view they chose since the study is relatively small. I believe it involves a couple hundred patients, 200 or 300 patients. Consequently, a more sensitive endpoint became necessary. Still, it's made up of endpoints all of us in the Alzheimer's field acknowledge as significant for measuring the disease; therefore, I believe it strengthens the evidence base indicating that going after amyloid using the correct antibody to reach plaque and clear plaque is the proper strategy.

Paul Matteis

analyst
#27

Hi there, thanks a lot for the chance to ask a question. I'd like to hear your thoughts on how far along you are in fine-tuning some of the important practical aspects tied to how aducanumab can be used? To be specific, my recollection is that during the trials there were 6 MRI scans within the initial 12 months. If approval comes, do you anticipate that would hold true once it's out in the real world? And should that be the case, what steps can your company take to genuinely improve how usable this is, rather than limiting it to just a modest number of leading academic sites that already possess these kinds of built-in resources? Many thanks.

Michel Vounatsos

executive
#28

Al?

Alfred Sandrock

executive
#29

Yeah, so MRI does have value when it comes to keeping tabs on ARIA, and our expectation is that once aducanumab gets approved — assuming that happens — there are going to be requirements for MRI monitoring. How much scanning and how often, though, is something that will need more conversation with regulators across the globe.

Michel Vounatsos

executive
#30

Sure. As for how we roll this out, we're clearly beginning with those key sites that handle the highest volumes and are prepared to provide treatment. As was noted before, those number in the hundreds, which is already a meaningful footprint. Bear in mind that a confirmation of amyloid beta will most likely be required, and naturally, as time goes on, we'll move further down the pyramid toward bigger targets.

Phil Nadeau

analyst
#31

Morning, and thanks for taking this. I've got one about the financials. Looking at how SPINRAZA has been performing in the U.S., Q4 '20 appears to show a drop of roughly 34% compared with Q4 '19. You mentioned COVID, and you also mentioned competition, as factors behind those numbers. I'm wondering whether you can put a figure on how much of that came from COVID, and then how much will come back once the pandemic fades, as opposed to competition and patients who may be gone for good? Thanks.

Michel Vounatsos

executive
#32

Thanks for asking. We're monitoring this pattern quite closely. Let me begin, and then Mike will chime in. To start, we're happy to have reached $2.1 billion in total SPINRAZA revenue for 2020 even with COVID. Within the U.S., according to what the team tells us, COVID accounts for most of the effect. Patients feel afraid of visiting the centers, which means they postpone their dosing. Certain sites were shut down, or had restricted capacity, or restricted staff available to administer doses; and finally, COVID is speeding up a number of shifts toward other treatments that are on the market. The highest point for switching came in September, and after that we saw those numbers come down. Also, which is quite encouraging for us, a number of patients have chosen to come back to SPINRAZA, whether because of efficacy, how effective they perceive it to be, or because of side effects. And finally, after the launch spike, demand for SPINRAZA picked back up as the year came to a close. Mike?

Michael McDonnell

executive
#33

Right, there isn’t much I can add there. What I’d say is that in the U.S., where competition has been made worse by COVID, we’re still seeing growth outside the U.S. Clearly, during a pandemic, the thought of taking something orally becomes more appealing, since it means you don’t have to visit a health care facility. That makes the prospect of moving from an injection to an oral therapy more significant in the situation we’re in now, while on the other hand, it’s somewhat less probable that someone would move away from an oral therapy to an injection under those circumstances. So as for what we observed in Q4 in the U.S., we’d chalk all of it up to competition made worse by COVID. Exactly how much comes from each factor is a bit difficult to determine precisely, but it’s both. And I believe the key takeaway here is that we still strongly believe in SPINRAZA’s efficacy and its safety profile, and we do expect it to keep becoming — it will stay a very important treatment choice, especially after we get past the pandemic.

Michel Vounatsos

executive
#34

Thus, our optimism regarding SPINRAZA persists. Once more, this asset holds significant importance. As has been stated on numerous occasions, its strength lies in efficacy, and ideally, as vaccination rates rise, that will show up more clearly in how the drug gets used instead of being viewed as a matter of convenience. Ultimately, the SUNFISH data still stands — part two of SUNFISH still stands, with one in two patients seeing disease progression, and our product continues to be exceptionally well supported by documentation, holding the broadest label, and we keep putting resources into innovative research.

Jay Olson

analyst
#35

Good morning, and thank you for taking my question. You brought up the positive implications from Lilly's Phase 2 data on donanemab. Could you walk us through how aducanumab's finding profile, its specificity, and its PK profile compare with donanemab? Thanks.

Alfred Sandrock

executive
#36

Sure. This is Al speaking. Aducanumab attaches to aggregated forms of a-beta — soluble oligomers and insoluble fibrils alike. Because both of those are concentrated within the plaque, aducanumab binds to the plaque itself. In fact, it was originally identified through an amyloid plaque immunoreactivity assay. And by going after the plaque, it clears amyloid from the brain quite effectively. Donanemab targets the pyroglutamated version of a-beta, and that form shows up in plaque early on. The idea is that it sort of grabs hold of the plaque, so to speak, and it makes up a piece of the dense core. That means it goes after plaque in that manner too, so basically these are separate approaches to attacking plaque. When it comes to PK, my knowledge of donanemab's PK is pretty limited, though because it's an antibody, my guess is it behaves in a broadly comparable way to other monoclonal antibodies — a half-life of about two weeks, and so forth.

Robyn Karnauskas

analyst
#37

Nice work. I appreciate you both for fielding my question. Here's another one for you, Al, regarding donanemab. Lilly's CFO noted that because of its distinctive clearance mechanism, it might be capable of delivering substantial plaque removal following a short course of treatment. I'm simply wondering, when you consider the competitive environment and presume aducanumab gets the green light, in what way — would you view intermittent dosing as able to compete with aducanumab? Also, in your view, how might the competitive environment develop given that kind of profile? Thank you.

Alfred Sandrock

executive
#38

Right. I appreciate that, Robyn; this should be fascinating. My view is the market is big, and my view is there's room for several therapeutic choices, which ideally will be there for patients. The idea of intermediate dosing or perhaps reducing the dose after altering a dose, following plaque removal, is a fascinating one. That's a thing that can be studied and is under evaluation for several drugs, aducanumab, BAN2401, and donanemab too. What I'd add is this: there's the impact on neurodegeneration when it comes to plaque removal, yet there could be additional impacts as well, ones that are more acute. When you hear from patients especially, you might have heard during the FDA Advisory Committee, that patients appear to experience adverse effects once they cease aducanumab, and afterward they recover a portion of those benefits once they resume treatment within a fairly brief window; and that's — and something comparable has been observed with other antibodies, BAN2401 included. That second element might be tied more to synaptic function, which could be tied more to the soluble oligomer aspect, and my view is that's something still to be discovered through upcoming studies.

Salim Syed

analyst
#39

Thanks a lot. We appreciate all the detail, folks, and especially everything you shared about aducanumab. Al, I've got just one more for you, this time on donanemab. When I look back at the FDA AdComm documents, there's a quoted line in there stating that these anti-amyloid beta antibodies can't be viewed as one signal class; at the molecular level they're distinct, and those distinctions affect how they work, covering things like eminent lists, binding characteristics, and so forth. That was a fairly forceful argument the FDA put forward in the briefing docs. And it sounds like your position now is that donanemab is strengthening the argument. So I'm just wondering how that gets squared. Should beta-amyloid antibodies be viewed as one class, or shouldn't they?

Alfred Sandrock

executive
#40

No. That's an excellent question, and I attempted to make roughly that point during my prepared remarks this morning. But the initial generation of antibodies didn't truly go after the amyloid plaque. Take solanezumab, a Lilly antibody, for instance — it attached to monosoluable monomeric amyloid, a-beta. And if you look at the 2012 paper regarding the plaque-specific antibody, the concern expressed there was that an antibody of that kind wouldn't reach the plaque and clear it, meaning plaque that was already there. So even though solanezumab was in development, Lilly started work on an antibody specific to plaque; and I think that's likely what those FDA documents were getting at — it isn't simply a matter of having an anti-amyloid antibody. What you need are antibodies that will go after the plaque and clear pre-existing amyloid plaque in patients. I think bapineuzumab too — bapineuzumab was nonselective. It attached to soluble monomeric as well as insoluble aggregated forms of amyloid, plus soluble aggregated. That created problems with dosing. So I think what they were saying is that solanezumab and bapineuzumab perhaps failed to demonstrate clinical efficacy for reasons like these, but we shouldn't presume that about this next generation of antibodies that target plaque more effectively. After all, we all took lessons from the early studies, correct? And so I think donanemab is one more instance where those that go after plaque and clear amyloid robustly in humans — and if you enroll early stage patients, carefully selected — you will observe efficacy.

Michel Vounatsos

executive
#41

All right, then. In our view, 2021 is going to be a year of major change for Biogen, and I appreciate everyone for tuning in to this call. Take care.

Operator

operator
#42

That brings us to the end of today's call, everyone. We appreciate your joining us, and at this point you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.